Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Richard Duke
Chairman
richard.duke@menogenix.com

Message the company or request a 1:1 meeting here

MenoGeniX is a phase 2 clinical-stage biotech company developing MNGX-102, a proprietary formulation of human granulocyte colony-stimulating factor (G-CSF), as a novel alternative to hormone therapy and anti-depressants to treat hot flashes and related vasomotor symptoms of natural and surgical menopause including arthritis.

Pitch Video

Slide Deck

Executive Summary